Health Care·Pharmaceuticals·$4.6B
Ligand Pharmaceuticals (LGND) is a healthcare company focused on developing and commercializing technologies that enhance drug development. With a market cap of $5 billion, it plays a significant role in the pharmaceutical industry, particularly in the areas of drug discovery and development.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will show how well Ligand has performed relative to expectations.
Revenue Growth
While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+325.57%
Avg Stock Reaction
+3.10%
In Q4 2025, Ligand reported an impressive EPS of $2.02, significantly exceeding expectations. The stock reacted positively, gaining 2.5% the following day.
Management Promises & Guidance
Overall, expectations are high for Ligand, given its history of beating EPS estimates. Investors are keen to see if this trend continues.
Bull Case
If Ligand continues its streak of strong earnings surprises, it could lead to further stock price appreciation and increased investor confidence.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, especially given its recent high performance.
Earnings Per Share (EPS)
N/AEPS is a key indicator of profitability and will show how well Ligand has performed relative to expectations.
Revenue Growth
N/AWhile specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.
New Partnerships or Licensing Deals
N/ANew partnerships can significantly impact Ligand's future revenue and growth potential.
The print will turn on these two things.
Q1
What will be the EPS reported for Q1-2026?
Given the company's strong history of beating EPS estimates, the reported number will be crucial for market sentiment.
Q2
What new partnerships or licensing deals have been secured?
New deals can significantly enhance Ligand's growth prospects and revenue potential, making this a key focus for investors.
Why consensus could be wrong
The Street may be underestimating the potential for Ligand to secure new partnerships, which could significantly boost future revenue.
Supporting Evidence
Ligand has a strong track record of exceeding EPS estimates, indicating robust operational performance.
Recent trends in the pharmaceutical industry suggest increased demand for innovative drug development partnerships.
Key Risk
If new partnerships are announced or if EPS exceeds $2.50, it could challenge current market expectations.
Pre-commit to what would confirm each case.
The market is debating whether Ligand can maintain its strong earnings momentum and secure new growth opportunities.
Bull Confirmed If
An EPS of $2.50 or higher would confirm the bull case and suggest continued strong performance.
Bear Confirmed If
An EPS below $1.50 would confirm the bear case, indicating potential issues in growth or profitability.
Implied Move
±N/A
There is no available options market data to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Ligand beats expectations, history suggests a potential stock increase of around 3.1%, confirming ongoing strong performance.
In-Line / Cautious
If results are in line but management provides cautious commentary, the stock may react modestly, reflecting uncertainty.
Miss
In the event of a miss, history suggests a potential decline, with past average reactions indicating a drop of around 2.94%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026